Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey ; volume:15 ; number:1 ; day:4 ; month:10 ; year:2014 ; pages:1-10 ; date:12.2014
BMC musculoskeletal disorders ; 15, Heft 1 (4.10.2014), 1-10, 12.2014
- Creator
-
Nota, Ingrid
- Contributor
-
Drossaert, Constance HC
Taal, Erik
Vonkeman, Harald E.
Van de Laar, Mart AFJ
SpringerLink (Online service)
- DOI
-
10.1186/1471-2474-15-333
- URN
-
urn:nbn:de:1111-2016043030252
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nota, Ingrid
- Drossaert, Constance HC
- Taal, Erik
- Vonkeman, Harald E.
- Van de Laar, Mart AFJ
- SpringerLink (Online service)
Other Objects (12)
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Variability in response to anti-rheumatic drugs
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Calprotectin bei DMARD (Disease Modifying Anti-Rheumatic Drug)-naiver früher rheumatoider Arthritis als Aktivitäts- und Verlaufsmarker unter Therapie
The Effect of Anti-rheumatic Drugs on the Skeleton
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Variability in response to anti-rheumatic drugs
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Calprotectin bei DMARD (Disease Modifying Anti-Rheumatic Drug)-naiver früher rheumatoider Arthritis als Aktivitäts- und Verlaufsmarker unter Therapie
The Effect of Anti-rheumatic Drugs on the Skeleton
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Variability in response to anti-rheumatic drugs
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Calprotectin bei DMARD (Disease Modifying Anti-Rheumatic Drug)-naiver früher rheumatoider Arthritis als Aktivitäts- und Verlaufsmarker unter Therapie